Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARAY
STRONG SELLAccuray Incorporated · Healthcare · United States · $53M · Avg Vol: $388K/d
COMPANY DESCRIPTION
Accuray Incorporated is a global radiation oncology company that designs, manufactures, and sells advanced radiotherapy systems, including the CyberKnife and TomoTherapy platforms. These systems deliver highly precise, personalized treatments for cancer patients while minimizing damage to surrounding healthy tissue. Accuray's competitive moat is established through its proprietary motion-tracking and synchronization technologies, which allow for real-time adaptation during treatment delivery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 429.9M | 447.6M | 446.6M | 458.5M | 2.2% | 428.6M | 406.3M | 413.0M | -5.1% |
| EPS | -0.06 | -0.10 | -0.16 | -0.02 | — | -0.37 | -0.35 | -0.30 | — |
| Shares | 93.5M | 96.5M | 100.2M | 112.6M | +20.5% | 119.0M | — | — | — |
| Debt | 199.5M | 205.0M | 210.7M | 176.4M | -4.0% | 182.4M | — | — | — |
| Equity | 53.2M | 53.7M | 45.1M | 81.2M | 15.1% | — | — | — | — |
| Op CF | -2.4M | 15.5M | -11.9M | 2.9M | -57.1% | -19.1M | — | — | — |
| Inv CF | -4.7M | -12.7M | -3.6M | -8.5M | — | — | — | — | — |
| Fin CF | -15.4M | -2.1M | -4.0M | -4.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARAY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARAY | Accuray Incorporated(you) | $53M | 18 | STRONG SELL |
| MDAI | Spectral AI, Inc. | $52M | 18 | STRONG SELL |
| LUNG | Pulmonx Corporation | $53M | 17 | STRONG SELL |
| COCH | Envoy Medical, Inc. | $51M | 14 | STRONG SELL |
| ELUT | Elutia Inc. | $51M | 23 | SELL |
| ECOR | electroCore, Inc. | $51M | 24 | SELL |
| OM | Outset Medical, Inc. | $75M | 15 | STRONG SELL |
| LNSR | LENSAR, Inc. | $69M | 11 | STRONG SELL |
| AVH.AX | AVITA Medical, Inc. | $115M | 19 | STRONG SELL |
| HYPR | Hyperfine, Inc. | $95M | 13 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%